350 results on '"Zerbini, Cristiano"'
Search Results
52. Effects of Odanacatib on Bone Structure and Quality in Postmenopausal Women With Osteoporosis: 5-Year Data From the Phase 3 Long-Term Odanacatib Fracture Trial (LOFT) and its Extension
53. Treatment Mode Preferences in Rheumatoid Arthritis: Moving Toward Shared Decision-Making
54. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)
55. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo
56. Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study)
57. MOESM1 of Burden of rheumatoid arthritis on patients’ work productivity and quality of life
58. Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis.
59. Teriparatide vs risedronate for osteoporosis Reply
60. Romosozumab FRAME Study: A Post Hoc Analysis of the Role of Regional Background Fracture Risk on Nonvertebral Fracture Outcome
61. Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial
62. SAFETY PROFILE OF UPADACITINIB IN RHEUMATOID ARTHRITIS: INTEGRATED ANALYSIS FROM THE SELECT PHASE 3 CLINICAL PROGRAM.
63. FRAX Modelo Brasil e os limites de intervenção médica
64. THU0167 SAFETY PROFILE OF UPADACITINIB IN RHEUMATOID ARTHRITIS: INTEGRATED ANALYSIS FROM THE SELECT PHASE 3 CLINICAL PROGRAM
65. OP0029 SWITCHING BETWEEN THE JAK1-SELECTIVE INHIBITOR-UPADACITINIB AND ADALIMUMAB FOLLOWING INITIAL NON-RESPONSE: CLINICAL AND FUNCTIONAL OUTCOMES AMONG RHEUMATOID ARTHRITIS PATIENTS
66. 074 Summary of indirect comparison to evaluate efficacy of baricitinib with targeted synthetic and biologic disease anti-rheumatic drugs in patients with rheumatoid arthritis
67. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme.
68. Fibromyalgia syndrome in patients infected with human immunodeficiency virus
69. Multicentric Castleman disease not associated with HHV-8 and HIV viruses
70. Maintenance of low disease activity and remission with etanercept–disease-modifying antirheumatic drug (DMARD) combination therapy compared with treatment with DMARDs alone in Latin American patients with active rheumatoid arthritis
71. The brazilian FRAX model: an introduction
72. Teriparatide vs risedronate for osteoporosis – Authors' reply
73. 219 Safety summary results of baricitinib focusing on serious infections events and preselected comorbidities
74. 233 Durability, maintenance and effects of dose reduction following prolonged treatment with baricitinib
75. Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies
76. Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment
77. Prediction of Remission and Low Disease Activity in DMARD-Refractory Patients with RA Treated with Golimumab
78. Romosozumab Treatment in Postmenopausal Women with Osteoporosis
79. Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty‐Four–Month, Phase III Study.
80. Doença de Castleman multicêntrica não associada aos vírus HHV-8 e HIV
81. Doença de Castleman multicêntrica não associada aos vírus HHV-8 e HIV
82. Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab
83. Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies.
84. Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs
85. Efficacy of Triamcinolone Hexacetonide versus Methylprednisolone Acetate Intraarticular Injections in Knee Osteoarthritis: A Randomized, Double-blinded, 24-week Study
86. Tofacitinib With Methotrexate in Third-Line Treatment of Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Trial
87. Patient and Physician Expectations of Add-On Treatment With Golimumab for Rheumatoid Arthritis: Relationships Between Expectations and Clinical and Quality of Life Outcomes
88. Effects of Up to 5 Years of Denosumab Treatment on Bone Histology and Histomorphometry: The FREEDOM Study Extension
89. Doença de Castleman multicêntrica não associada aos vírus HHV‐8 e HIV
90. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): Additional results from the monthly oral therapy with ibandronate for osteoporosis intervention (MOTION) study
91. Odanacatib in postmenopausal women with low bone mineral density: a review of current clinical evidence
92. Bone histology and histomorphometry: effects of 5 years of denosumab in the FREEDOM Extension
93. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
94. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
95. Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs.
96. Diretrizes para prevenção e tratamento da osteoporose induzida por glicocorticoide
97. In Memoriam: Sergio Ragi-Eis, MD, CCD, CDT (April 8, 1962–February 22, 2012)
98. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo
99. O uso clínico da densitometria
100. Osteoporose secundária a drogas
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.